Weight Loss Peptides
Peptides that regulate appetite, metabolism, and body composition for weight management.
Semaglutide
Semaglutide is a GLP-1 receptor agonist approved for diabetes and weight management. Learn about uses, dosage protocols, side effects, legal status, and clinical evidence.
Tirzepatide
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and weight loss. Learn about uses, dosage protocols, side effects, clinical trial data, and more.
Retatrutide
Retatrutide is a triple receptor agonist (GLP-1, GIP, and glucagon) producing 24.2% weight loss in Phase 2 and up to 28.7% in Phase 3 (TRIUMPH-4). March 2026 TRANSCEND-T2D-1 results show HbA1c reductions of up to -2.0% and 16.8% weight loss in type 2 diabetes. Learn about dosage, the emerging dysesthesia safety signal, comparison vs semaglutide and tirzepatide, FDA approval timeline, and clinical evidence.
AOD-9604
AOD-9604 is a modified HGH fragment (176-191) studied for fat loss. Learn about its mechanism, dosage, clinical trial results, side effects, and legal status.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza (diabetes) and Saxenda (weight loss). Learn about dosage, SCALE trials, side effects, and more.
Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist in Phase 3 trials for obesity and MASH. Clinical data shows up to 18.7% weight loss and 62% MASH resolution. Learn about mechanism, dosing, side effects, and FDA status.